What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. nurture) cohort? Where are we heading?
about
Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosusIdentification of two independent risk factors for lupus within the MHC in United Kingdom families.Comparison of ethnicity, gender, age of onset and outcome in South Africans with systemic lupus erythematosus.Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII)Spontaneous lupus-like syndrome in HLA-DQ2 transgenic mice with a mixed genetic background.MHC region and risk of systemic lupus erythematosus in African American women.The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claimsThree decades of progress in treating childhood-onset lupus nephritis.Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.Genetic risk factors for thrombosis in systemic lupus erythematosus.Why can't we find a new treatment for SLE?Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies.Epidemiologic, socioeconomic and psychosocial aspects in lupus erythematosus.Utilizing registries in systemic lupus erythematosus clinical research.Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies.The need to define treatment goals for systemic lupus erythematosus.Lupus in Latin-American patients: lessons from the GLADEL cohort.Prevalence and incidence of systemic lupus erythematosus in South Korea.Lupus (SLE): Existence and Impact of Depressive Symptomatology.Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.Lupus in Africa: can we dispel the myths and face the challenges?Ethnic disparities in health and disease: the need to account for ancestral admixture when estimating the genetic contribution to both (LUMINA XXVI).Systemic lupus erythematosus: clinical manifestations, treatment and economics.An evaluation of health-related quality of life in patients with systemic lupus erythematosus using PROMIS and Neuro-QoL.Predictors and outcome of systemic lupus erythematosus (SLE) admission rates in a large teaching hospital in sub-Saharan Africa.Antiphospholipid antibodies, steroid dose, arterial hypertension, relapses, and late-onset predict organ damage in a population of Colombian patients with systemic lupus erythematosus.Severe disease presentation and poor outcomes among pediatric systemic lupus erythematosus patients in South Africa.CCR5delta32 in systemic lupus erythematosus: implications for disease susceptibility and outcome in a Brazilian population.A unique antiphospholipid assay recognizing phospholipid mixture compared with criteria antiphospholipid immunoassays in lupus patients.Patients with familial and sporadic onset SLE have similar clinical profiles but vary profoundly by race
P2860
Q28301151-1D6A088C-F11B-42C8-B339-EC4089406548Q30837981-C7E7AE73-ADC4-45D6-8F1D-3F41C2ED94F9Q33436712-3812409B-39C1-4167-BFDD-2904701EB6FAQ33635924-2C28E5F4-F049-4AD4-8D55-D6FE9966F40AQ34032957-D8A727E4-8AAF-426B-BCE2-E2CE2D714F79Q35549151-E249BC98-E812-4AD1-80DB-849E4C61C5B3Q35654884-9ABCACC3-6F92-40E6-9917-A6AF07166EEAQ35983508-C729A750-2228-478C-B6B2-16216D194B39Q35993027-7A0242D2-3C78-4A30-85D0-3E28AE0EF0E7Q36807470-2B84C56B-2960-464A-840E-080025D285FBQ37236049-357EE26B-17B1-47DA-99F1-FB4AF564C667Q37332754-772A09CC-3707-4891-99B1-43DB26ADC1ABQ37778652-AC0E5321-D6BA-4B72-9136-5730F43B9046Q38011226-B00606BA-323F-4EC4-9247-37F81C5983E5Q38175493-A2AC32C2-EB16-4093-AC51-E808CBE4F048Q38232471-0173D886-92F3-4230-93B3-48CC02360560Q38362113-55160ABF-87DD-47E7-9EB7-83FA831F5565Q38423234-59C00A65-277D-4106-8BDA-B43079DC4ACEQ38549420-C664B229-EAE3-48BD-8995-AF76A201CEE4Q38771936-9C6B68AA-90CF-4E96-A15D-E373F13CEA5EQ44398366-93F30CD4-A3CB-49E1-8685-34977D1DA0B2Q45212503-7BC147BE-C7CD-4814-8546-F8F2F5008EA9Q46686656-88120E6A-3AA8-4442-980F-D8F0A8597F29Q47621117-7D1D3856-80AF-46F9-B888-B472EE8FE632Q47697086-24F8AEBC-A8DB-4398-ABAB-DFE2A27087F5Q48182257-3F1220ED-8470-4895-90A3-CA7D4ECBD1B4Q50231899-8A57960E-81B1-486A-9DB6-73D6EE09DDB3Q50920198-860C0631-E903-42F2-BAC5-71F8000EE5FAQ51381212-828AE232-9AEB-40FC-8C4E-5D55A13ABE73Q57329882-D34E46FE-010D-489B-AACA-05128AC8357C
P2860
What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. nurture) cohort? Where are we heading?
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
What have we learned from a 10 ...... cohort? Where are we heading?
@ast
What have we learned from a 10 ...... cohort? Where are we heading?
@en
What have we learned from a 10-year experience with the LUMINA
@nl
type
label
What have we learned from a 10 ...... cohort? Where are we heading?
@ast
What have we learned from a 10 ...... cohort? Where are we heading?
@en
What have we learned from a 10-year experience with the LUMINA
@nl
prefLabel
What have we learned from a 10 ...... cohort? Where are we heading?
@ast
What have we learned from a 10 ...... cohort? Where are we heading?
@en
What have we learned from a 10-year experience with the LUMINA
@nl
P2093
P1433
P1476
What have we learned from a 10 ...... cohort? Where are we heading?
@en
P2093
América G Uribe
Gerald McGwin
Graciela S Alarcón
P304
P356
10.1016/J.AUTREV.2003.11.005
P577
2004-06-01T00:00:00Z